ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2015
Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.
Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 74 citations in OpenAlex.
- Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.Nature medicine · 2019Trial
- Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.Genome medicine · 2016Trial
- Impact of molecular tumor board on clinical outcomes in patients with refractory solid tumors: a real-world study.The oncologist · 2026Article
- The Growth Modulation Index (GMI) as an Efficacy Outcome in Cancer Clinical Trials: A Scoping Review with Suggested Reporting Guidelines.Current oncology reports · 2025Article
- Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.Oncotarget · 2025Article
- The Application of Evidence-Based Medicine in Individualized Medicine.Biomedicines · 2023Article
- A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer.Cancer medicine · 2022Article
- Drivers of Start-Up Delays in Global Randomized Clinical Trials.Therapeutic innovation & regulatory science · 2021Article
- Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country.Iranian journal of pharmaceutical research : IJPR · 2021Article
- Strategies for Testing Intervention Matching Schemes in Cancer.Clinical pharmacology and therapeutics · 2020Review
- Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit.Biomedicines · 2020Article
- Bayesian Framework for Detecting Gene Expression Outliers in Individual Samples.JCO clinical cancer informatics · 2020Article
- Molecular profiling for precision cancer therapies.Genome medicine · 2020Review
- Comparative Tumor RNA Sequencing Analysis for Difficult-to-Treat Pediatric and Young Adult Patients With Cancer.JAMA network open · 2019Article
- The Pros and Cons of Incorporating Transcriptomics in the Age of Precision Oncology.Journal of the National Cancer Institute · 2019Review
- Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA.Cancer immunology research · 2019Article
- Effects of culture condition on epigenomic profiles of brain tumor cells.ACS biomaterials science & engineering · 2019Article
- Clinical outcomes after whole-genome sequencing in patients with metastatic non-small-cell lung cancer.Cold Spring Harbor molecular case studies · 2019Article
- Treatment According to Molecular Profiling in Relapsed/Refractory Cancer Patients: A Review Focusing on Latest Profiling Studies.Computational and structural biotechnology journal · 2019Review
- Precision Medicine Tools to Guide Therapy and Monitor Response to Treatment in a HER-2+ Gastric Cancer Patient: Case Report.Frontiers in oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 9 institutions in 6 countries.
Funding
Abstract
Advances in 'omics' technology and targeted therapeutic molecules are together driving the incorporation of molecular-based diagnostics into the care of patients with cancer. There is an urgent need to assess the efficacy of therapy determined by molecular matching of patients with particular targeted therapies. WINTHER is a clinical trial that uses cutting edge genomic and transcriptomic assays to guide treatment decisions. Through the lens of this ambitious multinational trial (five countries, six sites) coordinated by the Worldwide Innovative Networking Consortium for personalized cancer therapy, we discovered key challenges in initiation and conduct of a prospective, omically driven study. To date, the time from study concept to activation has varied between 19 months at Gustave Roussy Cancer Campus in France to 30 months at the Segal Cancer Center, McGill University (Canada). It took 3+ years to be able to activate US sites due to national regulatory hurdles. Access to medications proposed by the molecular analysis remains a major challenge, since their availability through active clinical trials is highly variable over time within sites and across the network. Rules regarding the off-label use of drugs, or drugs not yet approved at all in some countries, pose a further challenge, and many biopharmaceutical companies lack a simple internal mechanism to supply the drugs even if they wish to do so. These various obstacles should be addressed to test and then implement precision medicine in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.